CTNM
Contineum Therapeutics, Inc.
$14.53
-0.68%
2026-05-08
About Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Key Fundamentals
Forward P/E
-7.26
EPS (TTM)
$-1.94
ROE
-26.9%
Profit Margin
0.0%
Debt/Equity
2.78
Price/Book
2.05
Market Cap
$535.0M
Avg Volume (10D)
240K
Recent Breakout Signals
No recent breakout signals detected for CTNM.
Recent Price Range (60 Days)
60D High
$16.33
60D Low
$11.77
Avg Volume
277K
Latest Close
$14.53
Get breakout alerts for CTNM
Sign up for Breakout Scanner to receive daily notifications when CTNM triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Contineum Therapeutics, Inc. (CTNM) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CTNM daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CTNM operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.